Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases, leveraging its proprietary drug candidates such as Namodenoson and CF101. The company operates primarily in Israel and has a growing presence in Europe and the U.S., with clinical trials aimed at addressing significant unmet medical needs.
Can-Fite primarily generates revenue through licensing its drug candidates to larger pharmaceutical firms, which provides upfront payments and potential royalties on future sales. The company also seeks funding through grants to support its clinical trials, allowing it to minimize dilution while advancing its pipeline.
Results from clinical trials for key drug candidates like Namodenoson, particularly Phase III outcomes
Partnership announcements or licensing deals with larger pharmaceutical companies
Regulatory approvals or setbacks from health authorities in key markets such as the U.S. and Europe
Market sentiment around the biotechnology sector, influenced by broader healthcare trends
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Intense competition from other biotech firms with similar drug candidates
Potential for larger pharmaceutical companies to develop alternative therapies
High cash burn rate due to ongoing clinical trials and R&D expenses
Dependence on external funding sources for operational sustainability
low - The biotechnology sector is less sensitive to economic cycles as it primarily relies on R&D funding and regulatory approvals rather than consumer spending.
Interest rates affect Can-Fite's financing costs for R&D projects, but given its low debt levels, the impact is minimal. However, higher rates could dampen investor sentiment towards speculative biotech stocks, affecting valuation multiples.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, evidenced by an 85.2% decline over the past year.
